Arrowhead Pharmaceuticals Inc.ARWR
Close of Friday, October 23, 2026 · Arrowhead Pharmaceuticals Inc. is trading below its Pivot, OnlyAlpha's long-term trend line.
Price
$58.02
vs its Pivot
-19.3%
OnlyAlpha Score
36
Trend
Below its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| -12.2% | -12.6% | +54.2% | +30.7% | -2.6% |
No dividend in the last 12 months.
Who runs and owns it
In these funds
IBB · 0.62%IYH · 0.14%IYY · 0.01%IJH · 0.00%
Big investors that own it (latest 13F)
| Baker Bros. Advisors | 0.8% of holdings |
Suppliers, customers and partners
ARWR sells to
| Amgen | olpasiran royalties (assigned to Royalty Pharma) |
| Sarepta Therapeutics | global license & collaboration |
| GSK | exclusive worldwide license |
| Novartis | 2025 global license |
Partners and deals
| Royalty Pharma | bought olpasiran royalties |
| Takeda | fazirsiran US 50/50 profit share |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get ARWR in your free daily emailAfter every close: whether ARWR is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track ARWR free → Full Stock check
Track ARWR free → Full Stock check